Pfizer’s 2026 Midpoint: A Stock Under Pressure Amid Strategic Pivots
22.12.2025 - 14:27:05 | boerse-global.de
Pfizer shares enter the new week facing a complex set of signals. While the company is aggressively pursuing strategic growth in areas like obesity and oncology, lowered revenue forecasts and a fresh analyst downgrade are weighing on sentiment. The critical question for investors is whether these new ventures can generate revenue swiftly enough to offset the decline from its COVID-19 products.
The stock’s technical picture reflects the prevailing market skepticism. Year-to-date, the share price has declined by more than 17% when measured in euros, trading approximately 18% below its 52-week high. A Relative Strength Index (RSI) reading of just under 22 indicates the stock is in deeply oversold territory, suggesting significant downward pressure. Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Für. Immer. Kostenlos
